Charles Schwab’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.27M | Sell |
92,898
-649
| -0.7% | -$8.89K | ﹤0.01% | 2825 |
|
|
2025
Q1 | $1.03M | Buy |
93,547
+30
| +0% | +$332 | ﹤0.01% | 2829 |
|
|
2024
Q4 | $996K | Buy |
93,517
+3,024
| +3% | +$32.2K | ﹤0.01% | 2909 |
|
|
2024
Q3 | $1.15M | Buy |
90,493
+7,576
| +9% | +$96.2K | ﹤0.01% | 2879 |
|
|
2024
Q2 | $1.39M | Buy |
82,917
+20,037
| +32% | +$336K | ﹤0.01% | 2815 |
|
|
2024
Q1 | $943K | Hold |
62,880
| – | – | ﹤0.01% | 2813 |
|
|
2023
Q4 | $943K | Buy |
62,880
+16,486
| +36% | +$247K | ﹤0.01% | 2853 |
|
|
2023
Q3 | $650K | Buy |
46,394
+1,670
| +4% | +$23.4K | ﹤0.01% | 2947 |
|
|
2023
Q2 | $463K | Buy |
+44,724
| New | +$463K | ﹤0.01% | 3089 |
|
|
2022
Q2 | – | Sell |
-42,689
| Closed | -$372K | – | 3644 |
|
|
2022
Q1 | $372K | Hold |
42,689
| – | – | ﹤0.01% | 3163 |
|
|
2021
Q4 | $406K | Hold |
42,689
| – | – | ﹤0.01% | 3214 |
|
|
2021
Q3 | $719K | Buy |
42,689
+2,174
| +5% | +$36.6K | ﹤0.01% | 3006 |
|
|
2021
Q2 | $619K | Sell |
40,515
-338
| -0.8% | -$5.16K | ﹤0.01% | 3099 |
|
|
2021
Q1 | $796K | Sell |
40,853
-183
| -0.4% | -$3.57K | ﹤0.01% | 2927 |
|
|
2020
Q4 | $740K | Buy |
41,036
+1,066
| +3% | +$19.2K | ﹤0.01% | 2866 |
|
|
2020
Q3 | $772K | Sell |
39,970
-1,826
| -4% | -$35.3K | ﹤0.01% | 2737 |
|
|
2020
Q2 | $1.09M | Buy |
41,796
+1,232
| +3% | +$32.2K | ﹤0.01% | 2597 |
|
|
2020
Q1 | $724K | Buy |
40,564
+210
| +0.5% | +$3.75K | ﹤0.01% | 2578 |
|
|
2019
Q4 | $1.35M | Buy |
40,354
+1,169
| +3% | +$39K | ﹤0.01% | 2516 |
|
|
2019
Q3 | $934K | Buy |
39,185
+208
| +0.5% | +$4.96K | ﹤0.01% | 2594 |
|
|
2019
Q2 | $1.4M | Buy |
+38,977
| New | +$1.4M | ﹤0.01% | 2476 |
|